Added to YB: 2026-09-17
Pitch date: 2026-09-15
VRCA [neutral]
Verrica Pharmaceuticals Inc.
Author Info
No bio for this author
Company Info
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
Market Cap
$82.1M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.84
P/E
-2.54
EV/Sales
2.40
Sector
Pharmaceuticals
Category
growth
Biotech Conference Coverage: Week 2, Day 1 — Part 2: Verrica Pharmaceuticals Inc.
VRCA (quick overview): Verrica’s marketed YCANT franchise could expand from molluscum into common warts, whose US patient population is three to four times larger, without wholly new commercial infrastructure. Shionogi/Torii is expected to front the first $40M, roughly 90% of Phase 3 program costs; results are expected in Q1 and by mid-2027. VP-315 provides skin-oncology optionality but remains pre-pivotal, while the largest rerating likely depends on the two common-wart Phase 3 results.
Read full article (2 min)